KAMAS Health 2.0 Presentation
Upcoming SlideShare
Loading in...5
×
 

KAMAS Health 2.0 Presentation

on

  • 16,606 views

Kinect Abnormal Motion Assessment Score presentation from Health 2.0. See http://motionassessment.com for more.

Kinect Abnormal Motion Assessment Score presentation from Health 2.0. See http://motionassessment.com for more.

Statistics

Views

Total Views
16,606
Views on SlideShare
1,422
Embed Views
15,184

Actions

Likes
0
Downloads
16
Comments
0

19 Embeds 15,184

http://gregborenstein.com 12637
http://www.gregborenstein.com 1740
http://motionassessment.com 549
http://gregs-macbook-pro.local 50
http://www.motionassessment.com 46
http://gregs-macbook-pro-2.local 39
http://dhcp-18-111-23-39.dyn.mit.edu 38
http://abtasty.com 23
http://translate.googleusercontent.com 23
http://gregs-mbp.local:12491 18
http://www.google.com 8
https://www.google.com 3
url_unknown 3
http://www.google.de 2
http://www.gregborenstein.com&_=1409003784447 HTTP 1
http://gregborenstein.com.netzcheck.com 1
http://bootloaderblog.com 1
http://a0.twimg.com 1
http://gregborenstein.com&_=1409349412650 HTTP 1
More...

Accessibility

Categories

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

KAMAS Health 2.0 Presentation KAMAS Health 2.0 Presentation Presentation Transcript

  • March 21, 2011
    Copyright 2011: Team Triangle
    Kinect Abnormal Movement Assessment System (KAMAS)
    Team TriangleClaus C Becker, MSc, PhD, MBA Greg Borenstein, MPS (candidate) Johnny Hujol, MSCS Daniel Karlin, MD, MA Greg Kust, MPH, MBA
  • March 21, 2011
    Copyright 2011: Team Triangle
    Executive Summary
    Conceived and developed in 8 hours at Boston Code-a-Thon
    Symptomatic diseases with excess of movement
    Microsoft Kinect-based application to automate assessment
    Home-grown and integrated open-source code
    Multiple stakeholder perspectives (clinicians, payers, patients)
    Framework for future development
  • March 21, 2011
    Copyright 2011: Team Triangle
    Overview of Movement Disorders
    Focused on hyperkinetic movement disorders
    Dyskinesias, Choreas, Akathesias
    Neurological conditions affecting speed, fluency, and ease of movement; and the ability to stop movement
    KAMAS matches & complements existing clinical practices for the diagnosis & assessment of movement disorders
  • March 21, 2011
    Chorea van Sydenham
    http://www.youtube.com/watch?v=RsIQFeYOkAg
  • March 21, 2011
    Copyright 2011: Team Triangle
    Prevalence and Severity
  • March 21, 2011
    Copyright 2011: Team Triangle
    Problem in Current Practice
    Inadequate assessment of movement disorders (AIMS test)
    Standardization
    Frequency
    Inter-rater reliability poor, masking progression
    Disease progression, on a more granular & temporal basis
    Current assessment every 3-6 months, at best
    Gaps between assessments allow development of severe disease
    Response to therapy (e.g. efficacy, dosing, adverse events)
    Adherence to therapy
    Remote monitoring
  • March 21, 2011
    Copyright 2011: Team Triangle
    Our Approach
    Leverage MS Kinect
    Processing application using PrimeSense’s OpenNI middleware and OSCeleton library
    Tracks spatial hand & knee movement
    Calculates score based upon degree of involuntary motion
    Clinical scorecard: Severity score compared to baseline
    MPR* + Patient self-report + KAMAS** = Health Score
    *MPR: Medicine possession ratio
  • March 21, 2011
    Copyright 2011: Team Triangle
    KAMAS Demonstration
  • March 21, 2011
    Copyright 2011: Team Triangle
    Clinical Benefits
    Patient
    Less disruptive / more convenient
    Engaged participation and self care
    Improved care
    Closed feedback loops
    Earlier detection of non-response and disease progression
    Provider
    Clinical effectiveness & dose modification
    Adherence measures (prescription status)
    Time efficient
    Reliable, quantifiable scoring
    EMR integration (video & data)
    At home or in clinic
  • March 21, 2011
    Copyright 2011: Team Triangle
    Payer Benefits
    Less $ waste (quick detection of ineffective therapy)
    Avoid a lifetime of advanced disease costs
    Reduce risk of expensive side effects and irreversible disease
    Reduce hospitalizations and all cause total costs (1)
    Clinical assessment without an office visit
    Telemedicine compatible
    Low cost, transparent, reproducible, auditable
    Start-up costs not capital intensive
    “Efforts to promote medication adherence…may lead to cost savings for managed care systems”3
    1) Delea et al. CNS Drugs. 2011 Jan 1;25(1):53-66, 2) Wei et al. Amer J Ger Pharm. 2010 Aug;8(4):384-394, 3) Davis KL et al. Prevalence and cost of medication nonadherence in Parkinson's disease: evidence from administrative claims data. Mov Disord. 2010 Mar 15;25(4):474-80.
  • March 21, 2011
    Copyright 2011: Team Triangle
    Issues we wrestled with
    Short timeline (ad hoc project)
    Kinect development environment rapidly changing
    Investment needed to further validate and develop for clinical use
  • March 21, 2011
    Copyright 2011: Team Triangle
    Next Steps
    With interest from investors, refine software to include directions, progression measures, and increased range of movements
    Data archiving and security compliance
    Improve statistical treatment of data
    Clinical validation possible at Tufts Medical Center
  • March 21, 2011
    Copyright 2011: Team Triangle
    References
    http://www.neurologychannel.com/movementdisorders/overview-of-movement-disorders.shtml
    http://www.nlm.nih.gov/medlineplus/movementdisorders.html
    http://www.atlantapsychiatry.com/forms/AIMS.pdf
    http://www.webmd.com
    Delea et al. CNS Drugs. 2011 Jan 1;25(1):53-66,
    Wei et al. Amer J Ger Pharm. 2010 Aug;8(4):384-394
    Davis KL et al. Prevalence and cost of medication nonadherence in Parkinson's disease: evidence from administrative claims data. Mov Disord. 2010 Mar 15;25(4):474-80.
    Rosenheck, RA. Evaluating the cost-effectiveness of reduced tardive dyskinesia with secong-generation antipsychotics. B J Psychiatry. 2007 (191): 238-245.